- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03248427
Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer. (CORALLEEN)
CORALLEEN: A Phase 2 Clinical Trial of Multi-agent Chemotherapy or Letrozole Plus Ribociclib (LEE011) as Neoadjuvant Treatment for Postmenopausal Patients With Luminal B/HER2-negative Breast Cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a parallel, two-arm, randomized 1:1, stratified by tumor size and nodal involvement, open-label, multicenter, exploratory study in postmenopausal women with primary operable HR+/HER2-negative Luminal B breast cancer according to PAM50 intrinsic subtype to evaluate the clinical benefit and biological effects of ribociclib combined with letrozole.
The primary trial objective is to evaluate the ability of each treatment strategy to provide ROR-low score at surgery.
Luminal B patients will be randomized 1:1 to either letrozole plus ribociclib or chemotherapy.Two weeks after the first administration of the assigned treatment, patients will undergo a biopsy to assess early biological response to treatment, at Ki67 protein and gene expression level. After finalization of the assigned neoadjuvant treatment, patients will undergo surgery.
The primary endpoint, Rate of ROR-low (at surgery) after neoadjuvant treatment, according to the Prosigna test will be centrally assessed.
Baseline, Day 15 and post-treatment (surgical) primary breast tumor tissue samples should be available for each patient for molecular characterization A post-surgery visit will be performed within 28 days (7 days) from surgery, and will mark the end of the study for that patient
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain
- Hospital Clínic de Barcelona
-
Barcelona, Spain
- Hospital General de Catalunya
-
Barcelona, Spain
- Hospital Universitari Vall d' Hebrón
-
Barcelona, Spain
- Institut Catala d'Oncologia L'Hospitalet
-
Castelló, Spain
- Consorcio Hospitalario Provincial de Castellon
-
Cáceres, Spain
- Hospital San Pedro de Alcántara
-
Granollers, Spain
- Fundació Privada Hospital Asil de Granollers
-
Madrid, Spain
- Hospital Universitario 12 de Octubre
-
Madrid, Spain
- Centro Integral Oncologico Clara Campal
-
Madrid, Spain
- Hospital Quiron Madrid
-
Madrid, Spain
- Centro Oncológico MD Anderson International España
-
Madrid, Spain
- Hospital Rey Juan Carlos
-
Madrid, Spain
- Hospital Universitario Fundacion de Alcorcon
-
Madrid, Spain
- Hospital Universitario Fundacion Jimenez Diaz
-
Palma, Spain
- Hospital Universitari Son Espases
-
Santiago de Compostela, Spain
- Complexo Hospitalario Universitario De Santiago
-
Sevilla, Spain
- Hospital Virgen del Rocío
-
Sevilla, Spain
- Hospital Virgen Macarena
-
Valencia, Spain
- Fundación Instituto Valenciano de Oncología
-
Valencia, Spain
- Hospital Clinico Universitario de Valencia
-
Valencia, Spain
- Hospital Universitari Arnau de Vilanova de València
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Signed Informed Consent Form prior to any study-specific procedure.
- Female patients.
- Post-menopausal status and age ≥18 years.
Histologically confirmed invasive breast carcinoma, with all the following characteristics:
- Primary tumor ≥ 2cm in largest diameter as measured by breast MRI
- Stage I to stage IIIA breast cancer
- No evidence of distant metastasis (M0)
- Breast cancer eligible for primary surgery.
- Available pre-treatment FFPE core (Tru-cut) biopsy evaluable for PAM50 or possibility to obtain one. Minimal sample requirements are to have at least 2 tumor cylinders with a minimal tissue surface of 10 mm2 tissue, containing at least 10% tumor cells and having enough tissue to do at least 2 cuts of 10 micrometers each.
- Luminal B subtype as per PAM50 analysis of pre-treatment sample.
- ER-positive and/or PgR-positive and HER2-negative tumor by ASCO/CAP guidelines assessed locally.
- In the case of a multifocal tumor (defined as the presence of two or more foci of cancer within the same breast quadrant), the largest lesion must be ≥ 2 cm and designated the "target" lesion for all subsequent tumor evaluations and HR+/HER2-negative status must be documented in all the tumor foci.
- ECOG performance status of 0 or 1.
- Adequate hematological, renal and hepatic function.
- Ability and willingness to comply with study visits, treatment, testing and to comply with the protocol.
Exclusion criteria
- Any prior treatment for primary invasive breast cancer.
- Inoperable locally advanced or inflammatory (i.e., inoperable Stage III) breast cancer.
- Metastatic (Stage IV) breast cancer.
- Bilateral invasive breast cancer.
- Multicentric breast cancer, defined as the presence of two or more foci of cancer in different quadrants of the same breast.
- Patients who have undergone sentinel lymph node biopsy prior to study treatment.
- Inability or unwillingness to swallow pills.
- Malabsorption syndrome or other condition that would interfere with enteric absorption of study drugs.
- Participation in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.
- Patient with a Child-Pugh score B or C.
Patient has active cardiac disease or a history of cardiac dysfunction including any of the following:
- History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty or stenting) or symptomatic pericarditis within 12 months prior to screening.
- History of documented congestive heart failure (New York Heart Association functional classification III-IV).
- Documented cardiomyopathy.
- Patient has a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO).
- Clinical significant cardiac arrhythmias (e.g. ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g. bifascicular block, Mobitz type II and third-degree AV block)
- Long QT Syndrome or family history of idiopathic sudden death or congenital long QT syndrome.
- On screening 12-lead ECG, any of the following cardiac parameters (defined as the mean of triplicate ECGs: bradycardia (resting heart rate < 50), tachycardia (resting heart rate > 90), PR interval > 220 msec, QRS interval >109 msec, or QTcF interval ≥450 msec (using Fridericia's correction).
- Uncontrolled hypertension (Systolic blood pressure >160 mmHg or <90 mmHg and/or diastolic >100 mmHg).
- Active infection requiring intravenous (IV) antibiotics.
- Symptomatic hypercalcemia despite adequate management.
- Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
- Known human immunodeficiency virus (HIV) infection.
- Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, that may compromise compliance with the protocol, that may affect the interpretation of the results, or renders the patients at high risk from treatment complications.
- Significant traumatic injury within 3 weeks prior to initiation of study treatment.
- Major surgical procedure (not including minor procedures such as lymph node biopsy, tumor core biopsy, fine needle aspiration) within 4 weeks prior to initiation of study treatment or not fully recovered from any side effects of previous procedures.
- Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
- History of other malignancy within 5 years prior to screening, except for appropriately treated basal or squamous cell carcinoma, carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer.
- Hormone replacement therapy stopped less than 2 weeks before treatment start.
- Currently receiving or has received systemic corticosteroids until 2 weeks before treatment start or who have not fully recovered from side effects of such treatment. Following corticosteroid uses are permitted: single doses, topical applications (e.g. for rash), inhaled sprays (e.g. for obstructive airways diseases), eye drops or local injections (e.g. intra-articular)
- Known hypersensitivity to any of the excipients of ribociclib, letrozole, doxorubicin, cyclophosphamide or paclitaxel.
Patients currently on following medications, which cannot be interrupted 7 days prior treatment start:
- Any prohibited medication as per letrozole, doxorubicin, cyclophosphamide, or paclitaxel label.
- Herbal preparations/medications, dietary supplements.
- Medications that have a known risk to prolong the QT interval or cause Torsades de Pointe.
- Medications with a narrow therapeutic window and predominantly metabolized through CYP3A4/5.
- Strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelos, star-fruit and Seville oranges.
- Warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin or fondaparinux is allowed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ribociclib + Letrozol
Ribociclib: 600mg, 3-weeks-on/-week-off treatment Letrozole: 2.5mg daily; Six 28 days cycles
|
Ribociclib flat-fixed dose of 600 mg daily (three 200-mg capsules), days 1 to 21 of a 28-days cycle.
Other Names:
Daily continuous
|
Other: Chemotherapy
Chemotherapy treatment will consist of four cycles of AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days) followed by weekly paclitaxel during 12 weeks.
|
60 mg/m2 as a continuous IV perfusion
600 MG/M2 in a 30 minutes IV infusion
80 mg/m2, in one hour IV infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of ROR-low according to the Prosigna test.
Time Frame: 24 weeks
|
Rate of ROR-low after neoadjuvant treatment at surgery, according to the Prosigna test,as per central assessment
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Overall response rate (ORR)
Time Frame: 24 weeks
|
Tumor overall objective response rate (ORR), defined as the sum of Partial Responses (PR) and Complete Responses (CR) according to RECIST v1.1, as per Investigator's assessments by breast MRI.
|
24 weeks
|
pCR in the breast and axillary lymph nodes
Time Frame: 24 weeks
|
pCR is defined as the complete absence of invasive carcinoma in the breast and axillary lymph nodes on histological examination.
|
24 weeks
|
PEPI Score
Time Frame: 24 weeks
|
Preoperative endocrine prognostic index (PEPI) score in the ribociclib plus letrozole treatment arm compared to historical values
|
24 weeks
|
Residual Cancer Burden (RCB)
Time Frame: 24 weeks
|
Rate of residual cancer burden (RCB) score 0 or 1 (RCB0/1) after neoadjuvant treatment, according to the MD Anderson Cancer Center procedures, as per central assessment.
|
24 weeks
|
Rate of breast conserving surgery (BCS)
Time Frame: 24 weeks
|
Rate of breast conserving surgery
|
24 weeks
|
Decrease in Ki67 in both treatment arms.
Time Frame: At baseline, in week 2, and pre-surgery
|
Decrease in Ki67 in both treatment arms.
|
At baseline, in week 2, and pre-surgery
|
Incidence, duration and severity of Adverse Events (AEs)
Time Frame: Up to 24 weeks
|
Incidence, duration and severity of Adverse Events (AEs) assessed by the NCI Common Terminology for Classification of Adverse Events (CTCAE) version 4.
|
Up to 24 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Aleix Prat, PhD, H.Clinic de Barcelona/
- Principal Investigator: Joaquin Gavilá, MD, Fundación Instituto Valenciano de Oncología
Publications and helpful links
General Publications
- Villacampa G, Falato C, Paré L, Hernando C, Arumí M, Saura C, Gómez G, Muñoz M, Gil-Gil M, Izarzugaza Y, Ferrer N, Najera-Zuloaga J, Montaño A, Ciruelos E, González-Santiago S, Villagrasa P, Gavilá J, Prat A, Pascual T. Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial. Eur J Cancer. 2022 Oct;174:232-242. doi: 10.1016/j.ejca.2022.07.028. Epub 2022 Sep 5.
- Prat A, Saura C, Pascual T, Hernando C, Munoz M, Pare L, Gonzalez Farre B, Fernandez PL, Galvan P, Chic N, Gonzalez Farre X, Oliveira M, Gil-Gil M, Arumi M, Ferrer N, Montano A, Izarzugaza Y, Llombart-Cussac A, Bratos R, Gonzalez Santiago S, Martinez E, Hoyos S, Rojas B, Virizuela JA, Ortega V, Lopez R, Celiz P, Ciruelos E, Villagrasa P, Gavila J. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020 Jan;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7. Epub 2019 Dec 11.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Cyclophosphamide
- Paclitaxel
- Letrozole
- Doxorubicin
Other Study ID Numbers
- SOLTI1402
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
Clinical Trials on Ribociclib
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Fox Chase Cancer CenterTerminatedSquamous Cell Carcinoma of the Head and NeckUnited States
-
Novartis PharmaceuticalsRecruiting
-
Novartis PharmaceuticalsTemporarily not availableBreast Cancer
-
Novartis PharmaceuticalsCompletedNormal Hepatic Function | Impaired Hepatic FunctionUnited States
-
Hadassah Medical OrganizationUnknownSoft Tissue Sarcoma | LiposarcomaIsrael
-
Novartis PharmaceuticalsRecruiting
-
Nader SanaiNovartis; Barrow Neurological Institute; Ivy Brain Tumor CenterActive, not recruitingGlioblastoma Multiforme | MeningiomaUnited States
-
Assaf-Harofeh Medical CenterUnknownSoft-Tissue Sarcoma | Liposarcomas, Dedifferentiated | Liposarcoma - Well Differentiated | Liposarcoma; Mixed TypeIsrael
-
Children's Hospital Medical Center, CincinnatiNovartisTerminatedHigh Grade Glioma | Diffuse Intrinsic Pontine Glioma | Bithalamic High Grade GliomaUnited States